Compare General Motors Company (GM) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Motors Company vs Medpace Holdings Inc — how do they compare? General Motors Company trades at $82.74 (market cap $72.17B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: General Motors Company is far larger — about 4.3× Medpace Holdings Inc's market cap, and General Motors Company pays a 0.88% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Motors Company for 83 Days and Medpace Holdings Inc for 14 Days on average.
| GM | MEDP | |
|---|---|---|
Market Cap | $72.17B | $16.82B |
Volume | 4,900,304 | 223,093 |
Sector | Consumer Cyclical | Health |
52-Week High | $90.30 | $630.19 |
52-Week Low | $55.35 | $393.42 |
Typical Hold Time | 83 Days | 14 Days |
Enterprise Value | $175.15B | $16.44B |
Dividend Yield | 0.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Motors (GM) trades at $82.73, up 2.15% with a bearish technical signal despite recent earnings beats. The company shows mixed fundamentals with strong operating cash flow of $26.87B in 2025 but declining profit margins. Recent Q3 2026 sales fell 5.5% as EV demand weakens and Toyota challenges GM's U.S. sales leadership. Analyst consensus remains bullish with a $102.08 price target, though technical indicators show resistance at $83-$85 levels.
GM faces near-term headwinds from declining vehicle sales and margin pressure, but cost savings from eased fuel economy rules ($20.4B through 2031) and strong cash generation provide stability. The stock trades at attractive valuations (P/S 0.42) with 67% analyst buy ratings, though competitive threats and EV transition challenges require monitoring for sustained recovery.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About General Motors Company
General Motors Co. emerged from the bankruptcy of General Motors Corp. (old GM) in July 2009. GM has eight brands and operates under four segments: GM North America, GM International, Cruise, and GM Financial. The United States now has four brands instead of eight under old GM. The company lost its U.S. market share leader crown in 2021 with share down 280 basis points to 14.6%, but we expect GM to reclaim the top spot in 2022 as 2021 suffered from the chip shortage. GM Financial became the company's captive finance arm in October 2010 via the purchase of AmeriCredit.
Read more on GM →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
